

Anders Friberg, PhD

Born 15th of June 1980
Swedish citizen
E-mail: anders.friberg@bayer.com
Phone: +49 (0) 151 10606804



Professional Experience

Jan 2014 – present Scientist at Bayer Healthcare Pharmaceuticals, Lead Discovery (Berlin, Germany). Responsible for fragment screening by NMR on various drug discovery project, as well as structural elucidation of protein-ligand complexes by X-ray crystallography.

Jun 2011 – Nov 2013 Post-Doctoral Research Fellow, Vanderbilt University (Nashville, TN, USA). Fragment-based drug discovery in the lab of Prof. Dr. Stephen W. Fesik. Performed screening of fragment libraries and structural characterization of hits by NMR and X-ray crystallography. These data were used to support a chemistry program which developed high-affinity small molecule inhibitors for Mcl-1.

Nov 2010 – Mar 2011 Research Fellow, Technische Universität München, Chemie Department (Munich, Germany). Studied protein-protein and protein-ligand complexes by solution NMR spectroscopy in the lab of Prof. Dr. Michael Sattler.

Jan 2006 – Apr 2006 Research Internship, Medivir AB (Huddinge, Sweden). Applied a bioinformatics approach developed during my M.Sc. thesis on a drug development project.

Sep 1999 – Dec 1999 Research Internship, Unit of Molecular Toxicology at Karolinska Institutet (Stockholm, Sweden) in the group of with Prof. Dr. Magnus Ingelman-Sundberg. The research focused on molecular biology and included cloning, expression and purification of yeast membrane proteins.

Education

2006 – 2010 Ph.D., Helmholtz Zentrum München / Technische Universität München:
'Structure and molecular recognition of proteins linked to pre-mRNA splicing and transcriptional regulation'

2000 – 2005 M.Sc. in Biotechnology at the Royal Institute of Technology (KTH) in Stockholm with a focus on biomolecular and organic chemistry. The thesis project was entitled *'Computational Mapping of Active Sites'*.

Scientific Publications

A method for the second-site screening of K-Ras in the presence of a covalently attached first-site ligand
Sun Q, Phan J, **Friberg A**, Camper D, Olejniczak ET, Fesik SW (2014) J Biomol NMR
DOI 10.1007/s10858-014-9849-8

Studying weak and dynamic interactions of posttranslationally modified proteins using expressed protein ligation
Tripsianes K, Chu NK, **Friberg A**, Sattler M, Becker CF (2014) ACS Chem Biol. 9:347-52.

Discovery of potent myeloid cell leukemia 1 (Mcl-1) inhibitors using fragment-based methods and structure-based design. **Friberg A**, Vigil D, Zhao B, Daniels RN, Burke JP, Garcia-Barrantes PM, Camper D, Chauder BA, Lee T, Olejniczak ET, Fesik SW. (2013) J Med Chem 56:15-30.

Oral Disinfectants Inhibit Protein-Protein Interactions Mediated by the Anti-Apoptotic Protein Bcl-xL and Induce Apoptosis in Human Oral Tumor Cells. Gräber M*, Hell M*, Gröst C*, **Friberg A**, Sperl B, Sattler M, Berg T (2013) Angew Chem Int Ed 52:4487-91.

Strategies for the structural analysis of multi-protein complexes: lessons from the 3D-Repertoire project.
Collinet B, **Friberg A**, Brooks MA, van den Elzen T, Henriot V, Dziembowski A., Graille M, Durand D, Leulliot N, Saint André C, Lazar N, Sattler, M, Séraphin B, van Tilbeurgh H (2011) J Struct Biol 175:147-58.

Structure of an atypical Tudor domain in the Drosophila Polycomblike protein
Friberg A*, Oddone A*, Klymenko T, Müller J, Sattler M (2010) Protein Sci 19:1906-16.
* equal contribution

Structure and Ligand Binding of the Extended Tudor Domain of D. melanogaster Tudor-SN.
Friberg A, Corsini L, Mourao A, Sattler M (2009) J Mol Biol 387:921-34.